China NMPA approves Dupixent for adhesion dermatitis
-
Last Update: 2020-07-13
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Sanofi and Regenerative Pharmaceuticals recently announced that China's National Drug Administration, theAdministration of(NMPA), has approved Dupixent (dupilumab) treatment for patients with tertomatitis (AD) who cannot be controlled through local prescription drugs or appropriate therapiesEarlier, China's National Drug Administration (NMPA) had identified Dupixent (a dual inhibitor of IL-4 and IL-13) as "a clinically urgently needed overseas drug"the approval is based on the latest data from the global LIBERTY AD clinical trial, which included nearly 3,000 patientsThe trial evaluated Dupixent as a monotherapy or in combination with topical corticosteroids based on various efficacy indicators, including skin removal rates, overall disease severity and itchingSanofi CEO Paul Hudson said Dupixent has been authorised in the United States to treat moderate to severe adhesitisin adults, adolescents and children under the age of 6Dupixent (dupilumab) has also been approved by other countries, including European countries and Japan, for use in specific patients with moderate to severe adhesionitis
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
